STANDARD OF CARE

Courts now ask what is reasonable.

How the law now defines reasonable care, and how fetal weight estimation has been judged in court.

2024

The Restatement

In May 2024 the American Law Institute approved its first Restatement (Third) of Torts: Medical Malpractice. It moves the standard of care from prevailing custom toward reasonable care, judged on the evidence. Custom still counts. Evidence can outweigh it.1

1974

Helling v. Carey

The Washington Supreme Court held physicians liable for not giving a simple, available test that professional custom did not require. The test was inexpensive and harmless, and it could have prevented serious injury. A whole profession not using it was no defense.2

2025

Raposo v. United States

A federal court held that reasonable care means accounting for a 20 percent margin of error in estimated fetal weight, and that professional guidelines do not set the ceiling. Applied to a 4,200-gram estimate, the margin reached about 5,040 grams, past the point at which cesarean delivery should be considered. The court judged each provider against the estimate available at the time.3

IN COURT

Fetal weight estimates have produced verdicts in the tens of millions.4

Manning v. Pecos Valley of New Mexico

New Mexico, 2018. Fetal weight underestimated; the defense’s own experts called the care “indefensible.”

$73M

Swanson v. Northern Westchester Hospital Center

New York, 2009. Brachial plexus injury from shoulder dystocia.

$56M

Zhao v. United States

Southern District of Illinois, 2019.

$8.3M

Rodriguez v. Yale-New Haven Health

Connecticut, 2023.

$6.5M

Klutschkowski v. PeaceHealth

Oregon, 2011.

$1.9M

Know what each estimate can support.

  1. Restatement (Third) of Torts: Medical Malpractice, American Law Institute, May 2024; summarized in Aaron et al., JAMA 2025.
  2. Helling v. Carey, 83 Wn.2d 514 (Wash. 1974).
  3. Raposo v. United States, D. Alaska 2025.
  4. Published verdict reports. Amounts as reported at verdict; later reductions or settlements may differ.

A summary of published holdings and verdicts, not legal advice. Growth Intelligence is not an FDA-cleared device; it is clinical decision support under the CDS exemption.